Physician profile
Ilya Lim
NPI 1235450479
$4,534.62
in general payments reported to CMS, 2019-2025
34 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $125 · 2021: $1,139 · 2022: $1,576 · 2023: $420 · 2024: $629 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.26 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $979.22 | 2021-2025 | |
| Pfizer INC. | $416.65 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $388.51 | 2020-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $274.68 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $228.42 | 2021-2024 | |
| Smith+Nephew, INC. | $168.72 | 2024-2025 | Grafix Pl, Grafix |
| Lilly USA, LLC | $164.18 | 2021-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $154.01 | 2021-2022 | |
| Organogenesis INC. | $153.47 | 2023-2024 | Affinity, Puraply, Novachor |
| Almirall LLC | $149.51 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $126.68 | 2023 | Acuvue |
| Ucb, INC. | $124.53 | 2021-2025 | Bimzelx |
| Idorsia Pharmaceuticals US INC | $121.82 | 2022 | |
| Amgen INC. | $115.62 | 2022-2025 | Otezla |
| Convatec INC. | $95.02 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $88.72 | 2021-2022 | |
| Incyte Corporation | $81.21 | 2021-2022 | |
| Genentech USA, INC. | $79.64 | 2019 | |
| Genzyme Corporation | $66.14 | 2021-2022 | |
| Horizon Therapeutics Plc | $66.12 | 2023 | Tepezza |
| Biofrontera INC. | $61.86 | 2021-2025 | Bf-Rhodoled, Ameluz, Rhodoled Xl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.73 | 2024-2025 | Spevigo |
| Axogen | $53.94 | 2022 | |
| Mimedx Group, INC. | $52.01 | 2024 | |
| Dermavant Sciences, INC. | $48.70 | 2023-2024 | Vtama |
| Dutch Ophthalmic, USA | $42.33 | 2024 | Eva, Combined Machine, Tissueblue |
| Galderma Laboratories, L.P. | $41.36 | 2022-2025 | Nemluvio |
| Surgenex LLC | $31.46 | 2025 | Renograft, Surgraft, Ardeograft |
| Biotissue Holdings INC. | $24.00 | 2024 | |
| Amarin Pharma, INC. | $19.04 | 2023 | |
| Mallinckrodt Hospital Products INC. | $15.86 | 2025 | Acthar |
| Strata Skin Sciences, INC. | $15.65 | 2024 | Xtrac |
| Merz North America, INC. | $14.09 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.